Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02026973 · ClinicalTrials.gov registry record · Phase 1
Impact of Endogenous E2 on SSI and GH Rebound
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
NCT02026973: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT02026973 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 62 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02026973, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
Study Summary
Endogenous estrogens maintain growth hormone (GH) secretion in postmenopausal women by potentiating endogenous GH-releasing hormone (GHRH) drive and restraining somatostatin inhibition of GH release.
Interventions
- DRUG Placebo
- DRUG Anastrozole
- DRUG Fulvestrant
- DRUG Somatostatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2014-03 |
| Est. Completion | 2015-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02026973
The ClinicalTrials.gov registry entry for NCT02026973 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02026973 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02026973 about?
NCT02026973 is a clinical study titled "Impact of Endogenous E2 on SSI and GH Rebound". Endogenous estrogens maintain growth hormone (GH) secretion in postmenopausal women by potentiating endogenous GH-releasing hormone (GHRH) drive and restraining somatostatin inhibition of GH release.
What is the current status of trial NCT02026973?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2014-03. Estimated completion is 2015-11.
What interventions are being tested in trial NCT02026973?
The interventions under investigation include: Placebo (DRUG), Anastrozole (DRUG), Fulvestrant (DRUG), Somatostatin (DRUG).
Who is sponsoring clinical trial NCT02026973?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.